Reported 1 day ago
Precigen, Inc. (PGEN) has secured a credit facility agreement worth up to $125 million to enhance its financial stability and expedite the commercialization of PAPZIMEOS, an innovative immunotherapy. This funding will allow Precigen to extend its reach into international markets and target pediatric and HPV-related conditions, positioning the company for substantial growth and revenue generation.
Source: YAHOO